Neuroscience×Cancer research

Neuroscience and oncology are fusing into 'cancer neuroscience' — the study of how nerves innervate, wire into, and electrically drive tumors, and how the same gut-brain-immune axes that modulate neurodegeneration also modulate tumor immunity. Shared single-cell atlases, CRISPR, epigenetics, and microbiome biology give both fields a common toolkit to map neuron-tumor synapses and neural control of cancer growth.

Both fields already stand on the same bridges — In vivo models, human brain tissue, epigenetics, CRISPR, extracellular matrix, and stem-cell biology — and 85 authors publish on both sides separately without yet co-writing. The representative papers show the tell: both fields independently converged on single-cell RNA-seq ecosystem mapping and the gut microbiome (microbiota-gut-brain axis on one side, microbiome modulating anti-PD-1 response on the other). High Adamic-Adar affinity (10.2) with 41 common neighbors signals a structurally primed, not-yet-realized merger.

Groups that already sit on the neural-glioma or perineural-invasion frontier and combine single-cell/spatial genomics with in vivo electrophysiology will win first. Second, microbiome-immunology labs that can translate the gut-brain-axis playbook into tumor-immune modulation. The advantage goes to institutions with paired neuroscience and comprehensive-cancer-center infrastructure under one roof.

A spatial + single-cell + in vivo electrophysiology study mapping functional neuron-tumor synapses in a peripheral solid tumor (e.g., pancreatic or gastric), then CRISPR-perturbing candidate neurotransmitter/receptor genes to test whether silencing tumor innervation slows growth — with a parallel arm testing microbiome modulation of that neural-tumor axis.